Subtopic Deep Dive

IL-33 in Allergic Inflammation
Research Guide

What is IL-33 in Allergic Inflammation?

IL-33 is an alarmin cytokine released from epithelial and endothelial cells that drives type 2 inflammation in allergic diseases including asthma, atopic dermatitis, and anaphylaxis.

IL-33 signals through ST2 receptor on group 2 innate lymphoid cells (ILC2s) and Th2 cells to promote IL-5, IL-13, and IgE production (Moussion et al., 2008, 1147 citations). Genomewide association studies link IL-33/ST2 pathway variants to asthma susceptibility across ages (Moffatt et al., 2010, 2004 citations). House dust mite allergens trigger IL-33 release from airway cells via TLR4, initiating allergic responses (Hammad et al., 2009, 1138 citations).

Curated Papers

Key Challenges

Why It Matters

IL-33 blockade reduces eosinophilic inflammation in asthma models unresponsive to IL-4/IL-13 inhibitors, as type 2 inflammation varies across patients (Fahy, 2014, 1566 citations). In atopic dermatitis and anaphylaxis, IL-33 drives ILC2 activation post-infection or allergen exposure, restoring lung homeostasis while exacerbating allergy (Monticelli et al., 2011, 1248 citations). Disease-associated IL-33 functions position it as a biomarker for stratifying trials targeting severe allergic inflammation (Liew et al., 2010, 995 citations).

Key Research Challenges

Heterogeneous Asthma Endotypes

Type 2 inflammation driven by IL-33 occurs in most but not all asthma patients, complicating trial designs (Fahy, 2014). GWAS identify IL33/ST2 variants yet require functional validation in diverse populations (Moffatt et al., 2010). Biomarker stratification remains imprecise for IL-33 high responders.

Epithelial Damage Signaling

IL-33 release as alarmin from damaged epithelium needs precise triggers beyond allergens like house dust mite via TLR4 (Hammad et al., 2009). Constitutive nuclear expression challenges inducible cytokine models (Moussion et al., 2008). Integration with microbiota-immune interactions unclear (Zheng et al., 2020).

ILC2 Hyperactivation Risks

ILC2s promote tissue repair post-influenza but amplify allergic inflammation via IL-33/ST2 (Monticelli et al., 2011). Balancing homeostasis and pathology in chronic models elusive. Blockade efficacy in preclinical anaphylaxis models unproven.

Essential Papers

Interaction between microbiota and immunity in health and disease

Danping Zheng, Timur Liwinski, Eran Elinav · 2020 · Cell Research · 3.6K citations

Abstract The interplay between the commensal microbiota and the mammalian immune system development and function includes multifold interactions in homeostasis and disease. The microbiome plays cri...

A Large-Scale, Consortium-Based Genomewide Association Study of Asthma

Miriam F. Moffatt, Marta Gut, Florence Démenais et al. · 2010 · New England Journal of Medicine · 2.0K citations

Asthma is genetically heterogeneous. A few common alleles are associated with disease risk at all ages. Implicated genes suggest a role for communication of epithelial damage to the adaptive immune...

Type 2 inflammation in asthma — present in most, absent in many

John V. Fahy · 2014 · Nature reviews. Immunology · 1.6K citations

Inflammatory mechanisms in patients with chronic obstructive pulmonary disease

Peter J. Barnes · 2016 · Journal of Allergy and Clinical Immunology · 1.5K citations

IL-6 in inflammation, autoimmunity and cancer

Toshio Hirano · 2020 · International Immunology · 1.3K citations

Abstract IL-6 is involved both in immune responses and in inflammation, hematopoiesis, bone metabolism and embryonic development. IL-6 plays roles in chronic inflammation (closely related to chroni...

Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus

Laurel A. Monticelli, Gregory F. Sonnenberg, Michael C. Abt et al. · 2011 · Nature Immunology · 1.2K citations

The IL-1-Like Cytokine IL-33 Is Constitutively Expressed in the Nucleus of Endothelial Cells and Epithelial Cells In Vivo: A Novel ‘Alarmin’?

Christine Moussion, Nathalie Ortéga, Jean‐Philippe Girard · 2008 · PLoS ONE · 1.1K citations

Together, our results indicate that, unlike inducible cytokines, IL-33 is constitutively expressed in normal human tissues. In addition, they reveal that endothelial cells and epithelial cells cons...

Reading Guide

Foundational Papers

Read Moussion et al. (2008) first for IL-33 alarmin discovery in epithelium; Moffatt et al. (2010) for asthma GWAS linking IL33/ST2; Hammad et al. (2009) for allergen-triggered mechanisms.

Recent Advances

Fahy (2014) on type 2 inflammation heterogeneity; Zheng et al. (2020) on microbiota-immune interplay with IL-33; Liew et al. (2010) on disease functions.

Core Methods

GWAS for genetic associations (Moffatt 2010); TLR4/epithelial cell assays (Hammad 2009); ILC2 functional studies post-infection (Monticelli 2011).

How PapersFlow Helps You Research IL-33 in Allergic Inflammation

Discover & Search

Research Agent uses searchPapers and exaSearch to find IL-33 asthma papers, then citationGraph on Moffatt et al. (2010) reveals 2004-cited GWAS connections to ST2 variants, while findSimilarPapers expands to ILC2 studies.

Analyze & Verify

Analysis Agent applies readPaperContent to extract IL-33 alarmin mechanisms from Moussion et al. (2008), verifies claims with CoVe against Hammad et al. (2009), and runs PythonAnalysis on citation data for statistical trends in type 2 inflammation papers using GRADE for evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in IL-33 blockade trials post-Fahy (2014), flags contradictions between constitutive vs. inducible IL-33 expression, and Writing Agent uses latexEditText with latexSyncCitations for manuscripts, latexCompile for figures, and exportMermaid for ILC2 signaling diagrams.

Use Cases

"Extract IL-33 expression data from asthma GWAS papers and plot citation trends."

Research Agent → searchPapers('IL-33 asthma GWAS') → Analysis Agent → runPythonAnalysis(pandas plot of citations from Moffatt 2010) → matplotlib trend graph of 2004+ citations.

"Draft LaTeX review section on IL-33 alarmin in epithelial damage."

Synthesis Agent → gap detection (Moussion 2008 vs Hammad 2009) → Writing Agent → latexEditText('IL-33 alarmin review') → latexSyncCitations([Moffatt2010, Liew2010]) → latexCompile PDF.

"Find GitHub repos analyzing IL-33/ST2 single-cell RNA-seq datasets."

Research Agent → paperExtractUrls(Hammad 2009) → Code Discovery → paperFindGithubRepo → githubRepoInspect for airway allergen scripts.

Automated Workflows

Deep Research workflow conducts systematic review of 50+ IL-33 allergy papers: searchPapers → citationGraph → DeepScan 7-steps with CoVe checkpoints on Moffatt (2010) GWAS. Theorizer generates hypotheses on IL-33/microbiota links from Zheng (2020), chaining readPaperContent → gap detection → theory export. DeepScan verifies ILC2 pathways in Monticelli (2011) via runPythonAnalysis on inflammation metrics.

Try Doxa for IL-33 in Allergic Inflammation Research

Frequently Asked Questions

What defines IL-33's role in allergic inflammation?

IL-33 acts as an alarmin from epithelial/endothelial nuclei, signaling ST2 on ILC2s/Th2s to drive type 2 responses in asthma and dermatitis (Moussion et al., 2008).

What are key methods studying IL-33 in allergy?

GWAS identify IL33/ST2 risk alleles (Moffatt et al., 2010); TLR4 blockade tests confirm allergen-triggered release (Hammad et al., 2009); ILC2 transfer models assess inflammation (Monticelli et al., 2011).

What are seminal papers on this topic?

Moffatt et al. (2010, 2004 citations) links IL-33 to asthma genetics; Fahy (2014, 1566 citations) profiles type 2 endotypes; Moussion et al. (2008, 1147 citations) establishes alarmin role.

What open problems exist?

Stratifying IL-33-high asthma patients for biologics; integrating microbiota effects (Zheng et al., 2020); proving blockade in human anaphylaxis beyond models.